Berenberg Bank Raises Moderna (NASDAQ:MRNA) Price Target to $42.00

Moderna (NASDAQ:MRNA) had its target price boosted by investment analysts at Berenberg Bank from $33.00 to $42.00 in a research note issued to investors on Thursday. The brokerage currently has a “hold” rating on the stock. Berenberg Bank’s price objective would suggest a potential upside of 23.31% from the stock’s current price.

A number of other equities research analysts have also issued reports on MRNA. Sanford C. Bernstein started coverage on Moderna in a research report on Thursday, October 17th. They issued a “market perform” rating and a $55.00 target price on the stock. JPMorgan Chase & Co. lowered their price objective on shares of Moderna from $59.00 to $45.00 and set an “underweight” rating on the stock in a report on Tuesday, November 26th. Wolfe Research began coverage on shares of Moderna in a research report on Friday, November 15th. They issued an “underperform” rating and a $40.00 price objective on the stock. Bank of America reaffirmed an “underperform” rating and issued a $41.00 target price on shares of Moderna in a research report on Tuesday, December 10th. Finally, Jefferies Financial Group cut their price target on shares of Moderna from $65.00 to $55.00 and set a “hold” rating on the stock in a research report on Tuesday, October 15th. Four equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $75.58.

Moderna Stock Up 0.9 %

Shares of MRNA stock opened at $34.06 on Thursday. Moderna has a 12-month low of $31.94 and a 12-month high of $170.47. The company has a quick ratio of 4.20, a current ratio of 4.39 and a debt-to-equity ratio of 0.05. The firm has a fifty day moving average of $40.85 and a 200-day moving average of $66.75. The company has a market capitalization of $13.11 billion, a price-to-earnings ratio of -5.85 and a beta of 1.60.

Moderna (NASDAQ:MRNA) last released its earnings results on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.89) by $1.92. The firm had revenue of $1.90 billion during the quarter, compared to analysts’ expectations of $1.25 billion. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The company’s revenue was up 3.8% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.39) EPS. As a group, equities research analysts predict that Moderna will post -9.3 earnings per share for the current fiscal year.

Insider Buying and Selling at Moderna

In other news, insider Shannon Thyme Klinger sold 1,418 shares of the business’s stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $42.79, for a total transaction of $60,676.22. Following the completion of the sale, the insider now owns 19,717 shares in the company, valued at $843,690.43. The trade was a 6.71 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders sold 2,664 shares of company stock valued at $115,210 in the last quarter. 15.70% of the stock is currently owned by insiders.

Institutional Trading of Moderna

Several hedge funds have recently added to or reduced their stakes in MRNA. MassMutual Private Wealth & Trust FSB grew its holdings in Moderna by 58.2% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock valued at $44,000 after buying an additional 389 shares in the last quarter. Blue Trust Inc. boosted its position in shares of Moderna by 365.6% in the third quarter. Blue Trust Inc. now owns 731 shares of the company’s stock valued at $49,000 after acquiring an additional 574 shares during the period. Larson Financial Group LLC boosted its position in shares of Moderna by 53.5% in the third quarter. Larson Financial Group LLC now owns 910 shares of the company’s stock valued at $61,000 after acquiring an additional 317 shares during the period. Rakuten Securities Inc. grew its stake in shares of Moderna by 477.3% in the third quarter. Rakuten Securities Inc. now owns 941 shares of the company’s stock valued at $63,000 after acquiring an additional 778 shares in the last quarter. Finally, Itau Unibanco Holding S.A. bought a new position in Moderna during the second quarter worth about $75,000. 75.33% of the stock is owned by institutional investors and hedge funds.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.